The stock of Insight Molecular Diagnostics Inc (IMDX) has gone up by 6.44% for the week, with a 0.36% rise in the past month and a -19.71% drop in the past quarter. The volatility ratio for the week is 7.69%, and the volatility levels for the past 30 days are 5.53% for IMDX. The simple moving average for the past 20 days is -7.01% for IMDX’s stock, with a -0.27% simple moving average for the past 200 days.
Is It Worth Investing in Insight Molecular Diagnostics Inc (NASDAQ: IMDX) Right Now?
Moreover, the 36-month beta value for IMDX is 0.99. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for IMDX is 20.06M and currently, short sellers hold a 1.32% of that float. On June 18, 2025, IMDX’s average trading volume was 44.69K shares.
IMDX) stock’s latest price update
The stock of Insight Molecular Diagnostics Inc (NASDAQ: IMDX) has decreased by -12.19 when compared to last closing price of 3.20.Despite this, the company has seen a gain of 6.44% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee.
Analysts’ Opinion of IMDX
Many brokerage firms have already submitted their reports for IMDX stocks, with Lake Street repeating the rating for IMDX by listing it as a “Buy.” The predicted price for IMDX in the upcoming period, according to Lake Street is $5 based on the research report published on March 28, 2025 of the current year 2025.
IMDX Trading at -5.22% from the 50-Day Moving Average
After a stumble in the market that brought IMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.84% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMDX starting from James Andrea S., who purchase 97,561 shares at the price of $2.05 back on Feb 07 ’25. After this action, James Andrea S. now owns 151,231 shares of Insight Molecular Diagnostics Inc, valued at $200,000 using the latest closing price.
SMITH PATRICK W, the 10% Owner of Insight Molecular Diagnostics Inc, purchase 1,077,600 shares at $2.05 during a trade that took place back on Feb 07 ’25, which means that SMITH PATRICK W is holding 2,872,671 shares at $2,209,080 based on the most recent closing price.
Stock Fundamentals for IMDX
Current profitability levels for the company are sitting at:
- -15.24 for the present operating margin
- 0.53 for the gross margin
The net margin for Insight Molecular Diagnostics Inc stands at -15.15. The total capital return value is set at -1.16. Equity return is now at value -428.96, with -88.64 for asset returns.
Based on Insight Molecular Diagnostics Inc (IMDX), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -6.54. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -1464.33.
Currently, EBITDA for the company is -59.02 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of 16.65. The receivables turnover for the company is 1.09for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
To wrap up, the performance of Insight Molecular Diagnostics Inc (IMDX) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
